Therapeutic effect of L‐carnitine combined cyclic adenosine monophosphate and its influence on serum levels of IFN‐γ and IL‐4 in patients with viral myocarditis／ / 心血管康复医学杂志

ABSTRACT

To observe therapeutic effect of L‐carnitine combined cyclic adenosine monophosphate and its influence on serum levels of IFN‐γ and IL‐4 in patients with viral myocarditis .Methods: A total of 132 VMC pa‐tients treated in our hospital from 2017 to 2018 were randomly and equally divided into L‐carnitine group and com‐bined treatment group (received cAMP based on L‐carnitine group ) , both groups were treated for two weeks .Pe‐ripheral serum levels of IFN‐γ , IL‐4 , cardiac troponin T (cTnT) and creatine kinase isoenzyme MB (CK‐MB) be‐fore and two weeks after treatment , therapeutic effect and incidence of adverse drug reactions were observed and compared between two groups .Results: Compared with before treatment , there was significant rise in serum IL‐4 level , and significant reductions in serum levels of IFN‐γ , cTnT and CK‐MB in two groups after two‐week treat‐ment , P＝0. 001 all ;compared with L‐carnitine group , there was significant rise in serum IL‐4 level [ (47. 43 ± 9.17) ng／ml vs.(55. 38 ± 10.23 ) ng／ml] , and significant reductions in serum levels of IFN‐γ [ (65.22 ± 11.82 ) ng／ml vs .(52.18 ± 10.06) ng／ml] , cTnT [ (0. 37 ± 0.09) ng／ml vs.(0.18 ± 0.03) ng／ml] and CK‐MB [ (28.56 ± 5. 34) U／L vs.(16. 22 ± 3. 47) U／L] in combined treatment group , P＝0.001 all.Total effective rate of com‐bined treatment group was significantly higher than that of L‐carnitine group (92.4% vs.80.3%) , P＝ 0.042. There was no significant difference in incidence rate of adverse drug reactions between two groups , P＝0. 784. Con‐clusion L‐carnitine combined cAMP can significantly reduce peripheral serum IFN‐γ level and increase IL‐4 level , regulate Th1／Th2 imbalance with significant therapeutic effect in VMC patients .And its safety is good .